![Evaluating Biomarkers and Treatments for Acute Kidney Injury in a Zebrafish Model](/rails/active_storage/representations/proxy/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBcjhCIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--b9dacef8e48ad71ba372de8999b0e1bd37a0b42b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCem9MWm05eWJXRjBTU0lJYW5CbkJqb0dSVlE2QzNKbGMybDZaVWtpRFRZd01IZzJNREErQmpzR1ZBPT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--a3b53ba1a0f83efef18f6e75a8d4ce784384bee2/brachydanio_rerio.jpg)
Coronary Artery Disease (CAD) is the leading cause of death in the United States, and 81% of Acute Kidney Injury (AKI) patients in the renal fibrosis stage later develop CAD. In this study, Mathew and Joykutty aimed to create a cost-effective strategy to treat AKI and thus prevent CAD using a model of the zebrafish, Danio rerio. They first tested whether AKI is induced in Danio rerio upon exposure to environmental toxins, then evaluated nitrotyrosine as an early biomarker for toxin-induced AKI. Finally, they evaluated 4 treatments of renal fibrosis, the last stage of AKI, and found that the compound SB431542 was the most effective treatment (reduced fibrosis by 99.97%). Their approach to treating AKI patients, and potentially prevent CAD, is economically feasible for translation into the clinic in both developing and developed countries.
Read More...